Eficacia de la electroacupuntura frente al dolor en la neuropatía periférica secundaria a los fármacos platinos en adultos.

• Bárbara Gómez de Segura García ^[1] ; María Vicente Molina ^[2] ; Marta Pérez Andrés ^[1] ; Víctor Antón Izquierdo ^[1] ; Lucía García Miguel ^[1] ; Pablo Fernández Hernando ^[1]
  1. [1] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  2. [2] Enfermera, Hospital Nuestra Señora de Gracia, Zaragoza.
• Localización: Revista Sanitaria de Investigación, ISSN-e 2660-7085, Vol. 2, Nº. 11 (Noviembre), 2021
• Idioma: español
• Enlaces
  • Texto completo
• Resumen
  • español

    Propósito: La neuropatía periférica inducida por quimioterapia (NPIQ) es un efecto secundario común y limitante de la dosis de citostático. Se ha observado que la prevalencia de la NPIQ en pacientes con tratamiento con medicamentos derivados de los platinos es muy alta. Dado que no se han probado procedimientos terapéuticos contra la NPIQ, estamos interesados en definir el rol que cumple la electroacupuntura (EA), y los datos preliminares han mostrado resultados prometedores.

    Métodos: En un estudio aleatorio con un diseño adaptable para grupo secuencial en pacientes con NPIQ, comparamos EA (LV3, SP9, GB41, Gb34, LI4, LI11, SI3, y HT3;) con el tratamiento de placebo. La potencia estadística en este ensayo se calculó para comparar los resultados de los tratamientos con EA con los tratamientos placebo.

  • English

    Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose- limiting side effect from cytostatic drugs, and, it has been observed that the prevalence of peripheral neuropathy in patients with treatments that involve platinum derivatives drugs is very high. Since there have been no proven therapeutic procedures against CIPN, we were interested in defining the role of electroacupuncture (EA) from which preliminary data has shown promising results.

    Methods: In a randomized trial with a group sequential adaptive design in patients with CIPN, we compared EA (LV3, SP9, GB41, GB34, LI4, LI11, SI3, and HT3; ) with placebo treatment. The statistical power in this trial was primarily calculated to prove EA only and compare the results we’ll have about the patients that have had EA with the ones that have had placebo treatment.

• Referencias bibliográficas
  • Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007 Dec; 20(6):719-25. Review.
  • Kedar A, Cohen ME, Freeman AI. Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum (II) treatment: a case report....
  • Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature....
  • Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration...
  • Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat...
  • Malik B, Stillman M. Chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep. 2008 Jun;12(3):165-74. Review.
  • Misra UK, Kalita J, Nair PP. Diagnostic approach to peripheral neuropathy.Annals of Indian Academy of Neurology. 2008;11(2):89-97. doi:10.4103/0972-2327.41875
  • Schröder S, Liepert J, Remppis A, Greten JH. Acupuncture treatment improves nerve conduction in peripheral neuropathy. Eur J Neurol. 2007...
  • Markman M. Chemotherapy-induced peripheral neuropathy: Underreported and underappreciated. Current Pain Head Rep 2006;10:275-8.
  • Weiss RB. Toxicity of chemotherapy – The last decade. Sem Oncol. 2006;33(1):1.
  • Antoine JC, Camdessanché JP. Peripheral nervous system involvement in patients with cancer. Lancet Neurol. 2007;6:75-86.
  • Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ. Advances in neuropathic pain: diagnosis,mechanisms, and treatment...
  • Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management and evaluation of chemotherapy induced peripheral neuropathy....
  • Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy....
  • Cersosimo RJ. Oxaliplatin associated neuropathy: a review. Ann Pharmacother2005;39(1):128-35
  • Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM. Clinical and experimental findings in humans and animals with chemo-therapy-induced...
  • Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR, et al. Cisplatin-induced peripheral neurotoxicity is dependent...
  • Mielke S, Mross K, Gerds TA, Schmidt A, Wäsch R, Berger DP, et al. Comparative neurotoxicity of weekly non-break paclitaxel infusions...
  • Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the...
  • Mileshkin L, Prince HM. The troublesome toxicity of peripheral neuropathy with thalidomide. Leuk Lymphoma. 2006;47:2276-9.
  • Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. National Cancer Institute of Canada Clinical Trials Group;National...
  • Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol. 2000;11:509-13.
  • Pace A, Bove L, Nisticò C, Ranuzzi M, Innocenti P, Pietrangeli A, et al. Vinorelbine neurotoxicity: clinical and neurophysio-logical findings...
  • Lee JJ, Low JA, Croarkin E, Parks R, Berman AW, Mannan N, et al. Changes in neurologic function tests may predict neurotoxi-city caused...
  • Markman M. Chemotherapy-associated neurotoxicity: an important side-effect- impacting on quality-rather than quantity, of life. J Cancer...
  • Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the Patient Neurotoxicity Questionnaire...
  • Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin J Oncol Nurs. 2007;11:361-76.
  • Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine....
  • Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Iconomou A, Kalofonos HP, et al. Peripheral neuropathy induced by administration...
  • Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, et al. Incidence and characteristics of peripheral...
  • Lanzani F, Mattavelli L, Frigeni B, Rossini F, Cammarota S, Petrò D, et al. Role of a pre-existing neuropathy on the course of bortezomib-induced...
  • Nurgalieva Z, Xia R, Liu CC, Burau K, Hardy D, Du XL. Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts...
  • Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemo-therapy-induced peripheral neuropathy: prevention and treatment strategies....
  • Bhagra A, Rao RD. Chemotherapy-induced neuropathy. Curr Oncol Rep. 2007;9:290-9.
  • Cavaletti G, Marmiroli P. The role of growth factors in the prevention and treatment of chemotherapy-induced peripheral neurotoxicity....
  • Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Corn-blath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy:...
  • Von Schlippe M, Fowler CJ, Harland SJ. Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis....
  • Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl...
  • Cavaletti G, Bogliun G, Marzorati L, Zincone A, Marzola M, Colombo N, et al. Peripheral neurotoxicity of taxol in patients previously...
  • Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer. 2006;42:24-30.
  • Loven D, Levavi H, Sabach G, Zart R, Andras M, Fishman A, et al. Long-term glutamate supplementation failed to protect against peripheral...
  • Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, et al. Randomized phase III study of docetaxel compared with paclitaxel...
  • Pronk LC, Hilkens PH, Van den Bent MJ, Van Putten WL, Stoter G, Verweij J. Corticosteroid co-medication does not reduce the incidence...
  • Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, et al. Liposomal vincristine in relapsed non-Hodgkin”s...
  • Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005;23:4553-60.
  • Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005;5 Suppl 1:S38-46.
  • De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line...
  • San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al; VISTA Trial Investigators. Bortezomib plus melphalan...
  • Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4:889-901.
  • Kim GP, Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol. 2007;3:281-94.
  • Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, et al. Incidence and characteristics of peripheral...
  • André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin...
  • Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, et al. Single-agent bortezomib in previously untreated multiple...
  • Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral...
  • Offidani M, Corvatta L, Marconi M, Malerba L, Mele A, Olivieri A, et al. Common and rare side-effects of low-dose thalidomide in multiple...